Market News / Story
Vir Biotechnology's VIR-5500 Wins FDA Fast Track for Late-line mCRPC
·
Vir Biotechnology announced FDA Fast Track designation for VIR-5500, a PSMA-targeted PRO-XTEN dual-masked T-cell engager for late-line metastatic castration-resistant prostate cancer. Key Highlights: FDA granted Fast Track designation to VIR-5500 to expedite development for late-line mCRPC. VIR-5500 is a PSMA-targeted PRO-XTEN dual-masked T-cell engager co-developed with Astellas. Phase 1 dose-expansion cohorts include monotherapy and combination regimens; Phase 3…